Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 5/20 | 0.70 |
| ▸ | TYK2 | P29597 | 6/20 | 0.36 |
| ▸ | JAK1 | P23458 | 5/20 | 0.36 |
| ▸ | CDK1 | P06493 | 1/20 | 0.36 |
| ▸ | CDK2 | P24941 | 1/20 | 0.36 |
| ▸ | SMG1 | Q96Q15 | 1/20 | 0.36 |
| ▸ | JAK2 | O60674 | 7/20 | 0.36 |
| ▸ | JAK3 | P52333 | 4/20 | 0.36 |
| ▸ | ABL1 | P00519 | 2/20 | 0.36 |
| ▸ | BCR | P11274 | 2/20 | 0.36 |
| ▸ | CAMK2D | Q13557 | 1/20 | 0.35 |
| ▸ | FLT3 | P36888 | 1/20 | 0.34 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.34 |
| ▸ | CDK9 | P50750 | 1/20 | 0.34 |
| ▸ | MARK3 | P27448 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17113444 | 0.98 | SYK (0.70) | SYKTYK2JAK1CDK1CDK2 | |
| SCHEMBL17113385 | 0.97 | SYK (0.75) | SYKTYK2JAK1CDK1CDK2 | |
| SCHEMBL18627953 | 0.89 | SYK (0.61) | SYKTYK2JAK1CDK1CDK2 | |
| SCHEMBL17113383 | 0.88 | SYK (0.65) | SYKTYK2JAK1CDK1CDK2 | |
| SCHEMBL17129840 | 0.87 | SYK (0.62) | SYKTYK2JAK1JAK2JAK3 | |
| SCHEMBL17113608 | 0.86 | SYK (0.63) | SYK | |
| SCHEMBL17113590 | 0.86 | SYK (0.69) | SYKTYK2JAK1CDK1CDK2 | |
| SCHEMBL17113521 | 0.86 | SYK (0.69) | SYKTYK2JAK1CDK1CDK2 | |
| SCHEMBL17113285 | 0.86 | SYK (0.69) | SYKTYK2JAK1CDK1CDK2 | |
| SCHEMBL17113491 | 0.85 | SYK (0.68) | SYKCDK2ABL1BCRCCNT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3122744-B1 | DIAZASPIROALKANEONE-SUBSTITUTED OXAZOLE DERIVATIVES AS SPLEEN TYROSINE KINASE INHIBITORS | AB SCIENCE (FR) | 2018-11-07 | — | — | EP | claimed |
| US-10053455-B2 | Diazaspiroalkaneone-substituted oxazole derivatives as spleen tyrosine kinase inhibitors | AB SCIENCE (FR) | 2018-08-21 | — | — | US | claimed |
| US-20180179195-A1 | DIAZASPIROALKANEONE-SUBSTITUTED OXAZOLE DERIVATIVES AS SPLEEN TYROSINE KINASE INHIBITORS | AB SCIENCE (FR) | 2018-06-28 | — | — | US | claimed |
| EP-3122744-A1 | DIAZASPIROALKANEONE-SUBSTITUTED OXAZOLE DERIVATIVES AS SPLEEN TYROSINE KINASE INHIBITORS | AB Science (FR) | 2017-02-01 | — | — | EP | claimed |
| WO-2015144614-A1 | DIAZASPIROALKANEONE-SUBSTITUTED OXAZOLE DERIVATIVES AS SPLEEN TYROSINE KINASE INHIBITORS | AB SCIENCE (FR) | 2015-10-01 | — | — | WO | claimed |
| EP-3122744-B1 | DIAZASPIROALKANEONE-SUBSTITUTED OXAZOLE DERIVATIVES AS SPLEEN TYROSINE KINASE INHIBITORS | AB SCIENCE (FR) | 2018-11-07 | — | — | EP | disclosed |
| US-10053455-B2 | Diazaspiroalkaneone-substituted oxazole derivatives as spleen tyrosine kinase inhibitors | AB SCIENCE (FR) | 2018-08-21 | — | — | US | disclosed |
| US-20180179195-A1 | DIAZASPIROALKANEONE-SUBSTITUTED OXAZOLE DERIVATIVES AS SPLEEN TYROSINE KINASE INHIBITORS | AB SCIENCE (FR) | 2018-06-28 | — | — | US | disclosed |
| US-20180179195-A1 | DIAZASPIROALKANEONE-SUBSTITUTED OXAZOLE DERIVATIVES AS SPLEEN TYROSINE KINASE INHIBITORS | AB SCIENCE (FR) | 2018-06-28 | — | — | US | disclosed |
| US-20180179195-A1 | DIAZASPIROALKANEONE-SUBSTITUTED OXAZOLE DERIVATIVES AS SPLEEN TYROSINE KINASE INHIBITORS | AB SCIENCE (FR) | 2018-06-28 | — | — | US | disclosed |
| WO-2015144614-A1 | DIAZASPIROALKANEONE-SUBSTITUTED OXAZOLE DERIVATIVES AS SPLEEN TYROSINE KINASE INHIBITORS | AB SCIENCE (FR) | 2015-10-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10053455-B2 | Diazaspiroalkaneone-substituted oxazole derivatives as spleen tyrosine kinase inhibitors | SYK, ZAP70, LCK | SYK 1/4885TYK2 36/4885JAK1 86/4885 |
| US-20180179195-A1 | DIAZASPIROALKANEONE-SUBSTITUTED OXAZOLE DERIVATIVES AS SPLEEN TYROSINE KINASE INHIBITORS | SYK, ZAP70, LCK | SYK 1/4885TYK2 36/4885JAK1 86/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.